Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 2/20 | 0.42 |
| ▸ | SRC | P12931 | 2/20 | 0.42 |
| ▸ | VCP | P55072 | 4/20 | 0.41 |
| ▸ | GSK3B | P49841 | 5/20 | 0.40 |
| ▸ | PSMC4 | P43686 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 2/20 | 0.38 |
| ▸ | RET | P07949 | 1/20 | 0.38 |
| ▸ | MGLL | Q99685 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13020180 | 0.86 | KDM4E (0.48) | ABL1KDM4EALDH1A1HTTEGFR | |
| SCHEMBL13020203 | 0.85 | ALDH1A1 (0.44) | KDM4EALDH1A1HTTEGFRSRC | |
| SCHEMBL13020171 | 0.84 | KDM4E (0.46) | KDM4EALDH1A1HTTEGFRSRC | |
| SCHEMBL13020126 | 0.84 | VCP (0.49) | KDM4EALDH1A1HTTEGFRSRC | |
| SCHEMBL3791047 | 0.83 | VCP (0.46) | KDM4EALDH1A1HTTEGFRSRC | |
| SCHEMBL13020022 | 0.77 | HTT (0.73) | ABL1KDM4EALDH1A1HTTEGFR | |
| SCHEMBL13020238 | 0.75 | HTT (0.73) | ABL1KDM4EALDH1A1HTTEGFR | |
| SCHEMBL3788091 | 0.75 | SRC (0.60) | ABL1EGFRSRCKDRRET | |
| SCHEMBL5063322 | 0.75 | VCP (0.67) | ABL1KDM4EALDH1A1HTTEGFR | |
| SCHEMBL13020166 | 0.74 | GSK3B (0.49) | EGFRSRCGSK3BKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100331297-A1 | MODULATION OF PROTEIN TRAFFICKING | FOLDRX PHARMACEUTICALS, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100331297-A1 | MODULATION OF PROTEIN TRAFFICKING | FOLDRX PHARMACEUTICALS, INC. (US) | 2010-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331297-A1 | MODULATION OF PROTEIN TRAFFICKING | RAB1A, COPB1, GOLT1B | ABL1 1725/4885KDM4E 4425/4885ALDH1A1 3475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.